You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Harvard Business School
AstraZeneca
Boehringer Ingelheim
Baxter

Last Updated: March 30, 2020

DrugPatentWatch Database Preview

Litigation Details for Alza Corporation v. Impax Laboratories Inc. (D. Del. 2005)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Alza Corporation v. Impax Laboratories Inc. (D. Del. 2005)

Small Molecule Drugs cited in Alza Corporation v. Impax Laboratories Inc.
Biologic Drugs cited in Alza Corporation v. Impax Laboratories Inc.
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for Alza Corporation v. Impax Laboratories Inc. (D. Del. 2005)

Date Filed Document No. Description Snippet Link To Document
2005-09-01 1 Exhibit A following US Patents, owned by Alza Corporation: U.S. Pat. Nos. 4,327,725; 4,612,008; 4,783;337; and 5,082…following US Patents, owned by Alza Corporation: U.S. Pat. Nos. 4,327, 725; 4,612,008; 4,783,337; and 5,082,668…Gilman, '7"]1 ed., Ch 23, p 534 (1940) 4,783,337 A 11/1988 wong et al. ................ 424/468 …) Umted States Patent <10) mem No.: US 6,919,373 131 Lam et al. (45) Date of Patent: Jul. 19, 2005 … (Contmued) CA (US); Padmaja Shivanand, FoREIGN PATENT DoCUMENTs Mountain View, CA (US); Atul D. Ayer, External link to document
2006-12-06 101 Redacted Document ownedbyAlzaCorporatinn: U..S l’at. Nos. 4,32‘{, 725; 4,612,008; 4,‘783,337;¢1:¢| 5.0€2,568.“6§ ofvrliichil mmporatedinititentizetybyreferencebereio…described in U.S. Patent Nos. 6,919,3 73 (“the ’373 patent"’) and 6,930,129 (“the ’ 129 patent”) (collectively…treatment methods claimed in the patents in suit. 18. I understand that the patents claim methods of` treating… aa United States Patent nn mem No..- Us 6,919,373 st thm et al. (45) Date of Patent: Jul. 19, 2005 (54…collectively “the patents in suit”). I understand that my opinion will be used in the above-captioned case External link to document
2007-01-05 111 Remark History Vol 1-2, 6,919,373 Prosecution History Vol 1-3 and 6,930,129 Prosecution History Vol 1-2) (dab) (… Patent Histories. Original document(s) on file in Clerk's Office. (1 Box with Prosecution History…September 2005 6 May 2009 1:05-cv-00642 Patent District Court, D. Delaware External link to document
2007-08-20 123 Exhibit A for Andrx to review the patent prosecution records of U.S. Patent No. 6,919,373, issued July 19, 2005 …“the ‘373 patent”), and U.S. Patent No. 6,930,129, issued August 16, 2005 (“the ‘129 patent), collectively…373 and ‘129 patents, some of the inventors named on the ‘373 patent and the ‘129 patent requested that…as an expert in patent application prosecution practice before the United States Patent and Trademark …concluding as Chief Administrative Patent Judge of the Board of Patent Appeals and Interferences (“BPAI External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Boehringer Ingelheim
Moodys
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.